HistoIndex chooses London BioScience Innovation Centre as European base

6 June 2013

Singapore-based medical imaging company HistoIndex has become the 50th life science company in the London BioScience Innovation Centre (LBIC).

Since its doors opened in 2001, LBIC has supported over 100 life science companies through the provision of high-spec laboratory, office, conference and hot-desking space for biotech start-ups and others in the sector.

Ken Larkin, LBIC’s CEO, said: “We offer a warm welcome to HistoIndex as our 50th current client. Our facilities and location offer a unique central London base for companies looking to operate in Europe, providing them with a strong foundation for connecting to our industry as part of a thriving community of growing life science companies based at the Centre.”

Gordon Innes, CEO of London & Partners, said: “The fact that HistoIndex has chosen London as its European base is testament to the city’s leading expertise in life sciences. LBIC is spearheading innovation for science and technology in London and it is this convergence of industries and talent that makes London world-leading for life science start-ups. HistoIndex’s commitment to the city recognises London as Europe's science and tech capital, with access to world-class academic centres, hospitals and the largest cluster of life science businesses.”

Dr Katarzyna Zarychta, HistoIndex, Vice President for Sales in Europe said: “HistoIndex, a Singaporean company with a proven expertise in Asia and with successfully established offices in Beijing is pleased to open a new office in London as the base for our multiple activities in Europe. We are delighted to be the 50th company in LBIC and to be connected to the life sciences community in the United Kingdom and Europe. We believe that it will offer us remarkable opportunities in extending and growing our activities. HistoIndex is indeed strengthening its presence in Europe as we are planning the imminent opening of a new servicing centre in London.”


To top